Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran.

BMC Health Serv Res · 2025 · PMC11871816 · PMID 40025460

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Budget impact analysis According to the results of BIA, after covering the combination regimen of rivaroxaban plus aspirin by insurance system, it causes an increasing trend in costs in the years 2023 to 2027 included 0.06%, 0.12%, 0.19%, 25%, and 31% respectively.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.